Sunshine Heart Appoints Jon Salveson to Board of Directors

Sunshine Heart Appoints Jon Salveson to Board of Directors 
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwire) -- 03/13/13 --
  Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) today announced that
Jon W. Salveson has been appointed to the Company's Board of
Directors. Mr. Salveson is the Vice Chairman, Investment Banking and
Chairman of the Healthcare Investment Banking Group at Piper Jaffray
Companies (NYSE: PJC). He also serves on the Board of CryoLife (NYSE:
CRY), a leading medical device company focused on cardiac and
vascular surgery.  
"Jon brings extensive corporate transaction and financing experience
to the company that will play an integral role as we mature in the
clinic and on corporate development fronts," said John Erb, Chairman
of Sunshine Heart's Board of Directors. "With C-Pulse's pivotal trial
and European post-market study about to commence, we welcome his
strategic input as the company transitions to the next phase of
growth."  
Mr. Salveson joined Piper Jaffray in 1993 as an Associate, was
elected Managing Director in 1999, and was named the Group Head of
Piper Jaffray's International Healthcare Investment Banking Group in
2001. Mr. Salveson was appointed Global Head of Investment Banking
and a member of the Executive Committee of Piper Jaffray in 2004, and
has served in his present position as Vice Chairman, Investment
Banking since July 2010. Mr. Salveson received his undergraduate
degree from St. Olaf College and an M.M.M. in finance from the
Kellogg Graduate School of Management at Northwestern University.  
About Sunshine(R) Heart 
 Sunshine Heart, Inc. (NASDAQ: SSH) (ASX:
SHC) is an early-stage global medical device company committed to the
commercialization of the C-Pulse System, an implantable, non-blood
contacting, heart assist therapy for the treatment of moderate to
severe heart failure. The C-Pulse System can be implanted using a
minimally invasive procedure and is designed to relieve the symptoms
of heart failure through the use of counter-pulsation technology,
which enables an increase in cardiac output, an increase in coronary
blood flow and a reduction in the heart's pumping load. Sunshine
Heart has completed an approved U.S. Food and Drug Administration
(FDA) feasibility clinical trial of the C-Pulse System and presented
the results in November 2011. In March, 2012, the FDA notified the
Company that it could move forward with an investigational device
exemption (IDE) application. Sunshine Heart received unconditional
approval from the FDA in November 2012 to initiate its pivotal trial.
In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse
System in Europe. Sunshine Heart is a Delaware corporation
headquartered in Minneapolis with a subsidiary presence in Australia.
The Company has been listed on the Australian Securities Exchange
(ASX) since September 2004 and on the NASDAQ Capital Market since
February 2012. For more information, please visit
www.sunshineheart.com. 
About the C-Pulse(R) Heart Assist System 
 The C-Pulse Heart Assist
System, or C-Pulse System, an investigational device in the United
States, Canada and countries that do not recognize the CE Mark
approval, utilizes the scientific principles of intra-aortic balloon
counter-pulsation applied in an extra-aortic approach to assist the
left ventricle by reducing the workload required to pump blood
throughout the body, while increasing blood flow to the coronary
arteries. Operating outside the patient's bloodstream, the
extra-aortic approach of the C-Pulse technology offers greater
flexibility, allowing patients to safely disconnect to have intervals
of freedom to perform certain activities such as showering. The
C-Pulse System may help maintain the patient's current condition and,
in some cases, reverse the heart failure process, thereby potentially
preventing the need for later stage heart failure therapies, such as
left ventricular assist devices (LVADs), artificial hearts or
transplants.  
Caution: Investigational device, limited by Federal (or United
States) Law to Investigational use. 
Forward-Looking Statements 
 Certain statements in this release are
forward-looking statements that are based on management's beliefs,
assumptions and expectations and information currently available to
management. All statements that address future operating performance,
events or developments that we expect or anticipate will occur in the
future are forward-looking statements, including without limitation,
our expectations with respect to future clinical trial activities and
results including patient enrollment in trials. These forward-looking
statements are subject to numerous risks and uncertainties, including
without limitation, the possibility that our clinical trials do not
meet their enrollment goals, meet their end-points or otherwise fail,
that regulatory authorities do not accept our application or approve
the marketing of the C-Pulse System, the possibility we may be unable
to raise the funds necessary for the development and
commercialization of our products, that we may not be able to
commercialize our products successfully in the EU and the other risk
factors described under the caption "Risk Factors" and elsewhere in
our filings with the U.S. Securities and Exchange Commission and ASX.
You should not place undue reliance on forward-looking statements
because they speak only as of the date when made and may turn out to
be inaccurate. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. We may not actually achieve
the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements. 
For further information, please contact:  
Media: 
Laura Forman 
Blueprint Life Science Group 
T: +1-415-375-3340  
Investor:
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc. 
T: +1-952-345-4200